Related by context. All words. (Click for frequent words.) 79 BRIM2 76 phase IIb clinical 75 Phase Ib II 75 phase Ib 74 phase IIa 74 alvespimycin 74 Phase Ib clinical 74 phase IIIb 74 phase IIa clinical 73 ongoing Phase 1b 73 oral ridaforolimus 73 LUX Lung 73 randomized Phase IIb 73 phase IIb 73 MERLIN TIMI 73 IMPACT DCM 73 Phase IIIb clinical 73 ORAL Sync 72 SUCCEED trial 72 Pivotal Phase III 72 HCV SPRINT 72 Randomized Phase II 72 GetGoal Phase III 72 Randomized Phase 72 Phase Ib IIa 72 BCIRG 72 phase IIb study 72 Phase 1a clinical 72 randomized controlled Phase 72 randomized controlled multicenter 72 confirmatory clinical 72 CHAMPION PCI 71 AVADO 71 placebo controlled Phase 71 multicenter Phase 71 pivotal bioequivalence 71 trastuzumab DM1 T DM1 71 Prostate AdenoCarcinoma Treatment 71 Combination REOLYSIN R 71 dose escalation clinical 71 HCV RESPOND 2 71 Phase III placebo controlled 71 Phase #/#a 71 CAMMS# 71 randomized Phase III 71 Phase IIb III 71 phase IIb trial 71 multicenter Phase II 71 multicenter placebo controlled 71 Phase IIB 71 Phase Ib study 71 multicenter randomized Phase 71 Edge STudy 70 evaluating tivozanib 70 ExTRACT TIMI 70 ADVANCE PD 70 Amrubicin 70 NO# [002] 70 multicenter randomized placebo controlled 70 Motesanib 70 Phase III psoriasis 70 forodesine 70 RECORD1 70 Aplidin 70 multicenter randomized controlled 70 BOLDER II 70 pharmacokinetic PK 70 ENDEAVOR III 70 evaluating mipomersen 70 SYMMETRY trial 70 PERSEUS 70 SPIRIT FIRST 70 placebo controlled clinical 70 treatment naive genotype 70 AVOREN 70 STRIDE PD 70 registrational Phase 69 riociguat 69 phase 2a 69 Initiated Phase 69 MAGE A3 ASCI 69 Initiate Phase 69 EDEMA3 69 trastuzumab emtansine T DM1 69 enzastaurin 69 Safinamide 69 randomized Phase 2b 69 number NCT# ClinicalTrials.gov 69 Phase IIa clinical 69 Clinical Antipsychotic Trials 69 prospective multicentre 69 AVERROES 69 multicenter multinational 69 TMC# C# 69 huC# DM4 69 ENESTnd 69 RE LY 69 Phase 2a clinical 69 Phase III Pivotal 69 ANCHOR trial 69 CLL8 69 pharmacokinetic PK study 69 Phase 1b clinical 69 IMPACT IMmunotherapy 69 assessing T DM1 69 AVN# Phase 69 EVEREST II 69 sunitinib malate 69 TASKi2 69 elotuzumab 69 HGS ETR1 69 initiated Phase Ib 69 APPRAISE 69 acyclovir Lauriad R 69 PCI ExTRACT TIMI 69 dose escalation Phase 69 Bayer HealthCare Onyx Pharmaceuticals 69 ToGA 68 blinded randomized placebo controlled 68 registrational 68 placebo controlled Phase III 68 multicenter phase 68 Phase III Clinical Trial 68 human IgG1 monoclonal 68 Pivotal Phase 68 Cloretazine ® 68 DASISION 68 relapsed MM 68 Phase 2b study 68 Phase III AFFIRM 68 NSABP B 68 SUTENT ® 68 refractory chronic lymphocytic 68 midstage clinical 68 FOLOTYN ® 68 Intervention Effectiveness 68 PEARL SC 68 Phase IIIb 68 APEX PD 68 virus HCV protease inhibitor 68 Phase III randomized 68 rALLy trial 68 XL# SAR# 68 fosbretabulin 68 HGS ETR2 68 PrevOnco 68 ZOLINZA 68 NSABP C 68 PRIMO CABG 68 recurrent malignant glioma 68 fidaxomicin Phase 68 BR.# 68 Zenvia Phase III 68 MEND CABG 68 EOquin TM 68 Phase IIb clinical 68 Phase #b/#a clinical 68 CUSTOM III 68 Xelox 68 multicentre randomized 68 Vitaxin 68 unblinding 68 rALLy clinical trial 68 placebo controlled randomized 68 rALLy 68 compound INCB# 68 EXPLORE Xa 68 TAXUS ATLAS 68 Proellex TM 68 Phase III randomized controlled 68 APEX AMI trial 68 PANVAC VF 68 tramiprosate Alzhemed TM 68 INCB# [001] 68 Phase IIA 68 Pirfenidone 68 Second Pivotal Phase 67 Randomized Double blind 67 PFO migraine 67 PIX# [002] 67 axitinib 67 Phase III VISTA 67 Phase III Trial 67 adecatumumab MT# 67 phase Ib clinical 67 ORACLE MS 67 multicenter clinical 67 Brentuximab Vedotin SGN 67 fidaxomicin Phase 3 67 novel VDA molecule 67 controlled multicenter Phase 67 YONDELIS 67 Phase 2b Clinical Trial 67 IIa clinical trial 67 Sorafenib HCC Assessment 67 NASDAQ CXSP announced 67 Phase 2a trial 67 receptor tyrosine kinase inhibitor 67 Phase #b/#a 67 Completes Patient Enrollment 67 recombinant PSMA vaccine 67 oral methylnaltrexone 67 metastatic castration resistant 67 recurrent glioblastoma multiforme 67 CALGB # [002] 67 PROTECT AF 67 UPLYSO 67 double blinded randomized 67 metastatic HRPC 67 Multicenter Phase 67 including eniluracil ADH 67 Enzastaurin 67 Ophena TM 67 PSMA ADC 67 PRE SURGE 67 ACAPODENE 67 rindopepimut 67 interferon gamma 1b 67 Quinamed 67 ELACYT 67 Ambrisentan 67 CLARITY study 67 CIMZIA TM certolizumab pegol 67 HuMax EGFr 67 Nasdaq PGNX today 67 phase IIb III 67 ENDEAVOR IV 67 Androxal TM 67 GOUT 67 multicenter prospective 67 Tesmilifene 67 landmark ATHENA 67 TG MV 67 galiximab 67 APTIVUS 67 Dacogen injection 67 Phase 1b 67 registrational trial 67 icatibant 67 Phase 1b clinical trials 67 Aflibercept 67 EMPHASIS HF trial 67 Temsirolimus 67 ABSORB clinical 67 keloid scarring 67 dose escalation trial 67 Phase IIb 67 IMA# 67 JAK inhibitor 67 IIa trial 67 sNDA submission 67 COMFORT II 67 crizotinib PF # 67 PF # [002] 67 ACTIVE W 67 lintuzumab 67 dose escalation phase 67 EURIDIS 67 neratinib 67 VICTOR E1 67 omacetaxine mepesuccinate 66 Phase III ADT 66 ABSORB trial 66 sorafenib tablets 66 BRAF inhibitor 66 CATIE AD 66 ThermoDox ® clinical 66 canakinumab 66 Phase 1b trial 66 REVIVE Diabetes 66 azilsartan medoxomil 66 ganetespib 66 MERIT ES 66 Phase Ib 66 Vicriviroc 66 Matrix Phase 2b 66 Hepatocellular Carcinoma HCC 66 Medullary Thyroid Cancer 66 trastuzumab DM1 66 ORENCIA ® 66 Phase Ia 66 DEB# 66 Phase 2b clinical 66 Azedra 66 Phase 2b 66 relapsing remitting MS RRMS 66 Phase 2a 66 MIVI III 66 treatment naïve genotype 66 Phase 2b trial 66 Randomized Double Blind 66 SPRYCEL ® 66 randomized multicenter trial 66 Randomised 66 TMC# [002] 66 imetelstat GRN#L 66 Glufosfamide 66 teriflunomide 66 biliary tract cancer 66 prospective randomized placebo 66 metastatic renal cell 66 mg/m2 cohort 66 Phase III 66 Pafuramidine 66 deforolimus 66 Solorel 66 Oral Fingolimod 66 Clinical Trial Results 66 ONTARGET 66 metastatic castrate resistant 66 Forodesine HCl 66 HORIZONS AMI trial 66 ACUITY trial 66 vemurafenib 66 elacytarabine 66 Severe Sepsis 66 Randomized controlled 66 Active Ulcerative Colitis 66 Phase IIb trials 66 prospective multicenter 66 ID NCT# 66 CYT# potent vascular disrupting 66 brivanib 66 PROSTVAC TM 66 randomized multicenter 66 unique alkylating agent 66 SNT MC# 66 INSPIRE Trial Phase III 66 ICON7 66 vismodegib 66 CLIRS 66 randomized discontinuation trial 66 AIR CF2 66 EGS# 66 CALGB 66 metaglidasen 66 OvaRex ® MAb 66 TEMSO 66 TransVax 66 metastatic hormone refractory 66 R# #mg BID 66 Screening Trial 66 HER2 positive metastatic breast 66 BRAF V#E mutation 66 IMPACT DCM clinical 66 Phase III ThermoDox 66 Ophena 66 Tarceva TM 66 Hsp# Inhibitor 66 AIM HIGH 66 oral prodrug 66 AVASTIN 66 ISEL 66 SABCS 66 #mg dose [002] 66 albiglutide 66 confirmatory Phase III 66 label multicenter randomized 66 severe hypercholesterolemia 66 opioid induced bowel dysfunction 66 ORAL Solo 66 Trastuzumab DM1 66 Pivotal Trial 66 ORENCIA R 66 budesonide foam 66 Ocrelizumab 66 Phase IIb trial 66 Exherin TM 66 TBC# 66 RE LY ® 65 Elagolix 65 PRECiSE 65 ABCSG 65 evaluating REVLIMID 65 IMC #B 65 Initiates Phase III 65 Begins Dosing 65 GAMMAGARD 65 Raptiva ® 65 untreated metastatic melanoma 65 DU #b 65 Arzerra TM 65 Genasense ® 65 Phase 1a 65 Initiates Phase II 65 GW# [003] 65 prospectively defined 65 Phase 2b Study 65 sorafenib Nexavar 65 radiation sensitizer 65 Zemplar Capsules 65 lintuzumab SGN 65 ALSYMPCA 65 antibody MAb 65 Sprycel dasatinib 65 cetuximab Erbitux 65 ZACTIMA 65 multicenter Phase III 65 evaluating T DM1 65 SAR# [004] 65 evaluating Vectibix 65 non nucleoside HCV 65 CINQUIL 65 EchoCRT 65 dimebon latrepirdine 65 Aplidin R 65 Cariprazine 65 Phase IIb Trial 65 non nucleoside inhibitor 65 Phase lll 65 PDX pralatrexate 65 evaluating Prochymal 65 Phase IIa trial 65 LungAlert TM 65 PROVENGE ® 65 systemic anaplastic large 65 LUMINATE 65 Achieves Primary Endpoint 65 TLK# 65 TRANSFORMS 65 Randomized Double Blind Placebo 65 PRIMO CABG2 65 oral FTY# 65 Phase 2a clinical trials 65 ospemifene 65 Phase III clinical 65 Phase IIb randomized 65 double blinded placebo 65 preclinical pharmacokinetic 65 evaluating Xcytrin 65 MGd 65 CCR5 mAb 65 Tanespimycin 65 Carotid Revascularization Endarterectomy vs. 65 Sapacitabine 65 ALN VSP Phase 65 tolevamer 65 Omacetaxine 65 Plicera 65 EDEMA4 65 CAPACITY trials 65 Curaxin CBLC# 65 Traficet EN 65 subanalysis 65 Prospective Randomized 65 lumiliximab 65 evaluating Actimmune 65 IL# PE#QQR 65 ILLUMINATE 65 bazedoxifene conjugated estrogens 65 Phase 2b kidney transplant 65 HGS# 65 Aurexis 65 Thiarabine 65 Virulizin R 65 BLA filing 65 Hedgehog Pathway Inhibitor 65 Golimumab 65 Nexavar sorafenib 65 CR# vcMMAE 65 ruxolitinib 65 mertansine 65 EDEMA3 trial 65 JOULFERON 65 alvimopan 65 velafermin 65 ACCEDE 65 Cethromycin 65 LBH# 65 CA9 SCAN 65 PreCISe 65 dependent kinase inhibitor 65 Vectibix panitumumab 65 Val HeFT 65 evaluating satraplatin 65 Afatinib 65 eliglustat tartrate 65 R#/MEM # 65 Meets Primary Endpoint 65 Genz # 65 EmbraceAC 65 PRESEPT 65 Pharmacokinetic 65 Ceflatonin 65 EGFR TKI 65 CIMZIA ™ 65 GSK# [001] 65 darapladib 65 eltrombopag 65 multicenter randomized 65 orally inhaled migraine 65 ECASS 65 cMET 65 controlled multicenter 65 TASKi3 65 lomitapide 65 Silodosin 65 Genasense oblimersen sodium Injection 65 MKC# MT 64 PROSTVAC VF 64 Zenvia ™ 64 Vernakalant 64 Linagliptin 64 oral deforolimus 64 ADAGIO study 64 Telbivudine 64 arzoxifene 64 evaluating satraplatin plus 64 gastrin analogue TT 64 Phase IIIb study 64 Screening Trial DMIST 64 Femara letrozole 64 brivaracetam 64 Alemtuzumab 64 NASDAQ CLDX 64 NVA# 64 REMINYL ® 64 REVIVE TA 64 huN# DM1 64 candidate CRLX# 64 Commences Phase 64 lenalidomide Revlimid R 64 Phase III HEAT 64 Phenoptin 64 dose cohorts 64 TransVax TM 64 OncoVEX GM CSF 64 NSABP 64 satraplatin Phase 64 ThermoDox R 64 mRCC 64 Multicenter 64 ASA# 64 GLP toxicology studies 64 JAK Inhibitor 64 Zybrestat 64 Multiple Ascending Dose 64 dose cohort 64 randomized multicenter Phase III 64 Bezielle 64 dosing cohort 64 AEG# 64 PSN# [002] 64 CARE HF 64 pertuzumab 64 posaconazole 64 BETAS 64 Dasatinib 64 ACTEMRA TM 64 Presents Positive 64 Endovascular Valve Edge 64 Oglemilast 64 telomerase therapeutic 64 OPT CHF 64 Annamycin 64 Study Evaluating 64 TELCYTA 64 Oral Calcitonin 64 http:/www.clinicaltrials.gov 64 #th Annual Interscience 64 mGluR5 NAM 64 telomerase inhibitor drug 64 pivotal Phase III 64 OMAPRO ™ 64 PROSTVAC ® 64 placebo controlled dose escalation 64 ASCO GI 64 Oral NKTR 64 MIST II 64 pharmacogenomic translational research 64 Velcade bortezomib 64 Ozarelix 64 NEO3 64 QLT# 64 BCX# 64 confirmatory Phase 3 64 PRECISE Trial 64 Hormone Refractory Prostate Cancer 64 tarenflurbil 64 Subgroup analysis 64 randomized multicentre 64 Randomized Study 64 CBLC# 64 LymphoStat B TM 64 Randomized Evaluation 64 solithromycin 64 ASCEND HF 64 Phase III Clinical Trials 64 investigational protease inhibitor 64 Pooled Analysis 64 viral kinetics 64 vidofludimus 64 Phase #/#a trial 64 eosinophilic asthma 64 PLCO 64 investigational oral hepatitis C 64 Medidur TM FA 64 DIRECT Trial 64 CEQ# 64 GSK# [002] 64 Cloretazine 64 Renal Cell Carcinoma RCC 64 AP# [003] 64 RIO Lipids 64 Topline Results 64 IIa Clinical Trial 64 desvenlafaxine succinate 64 LAB CGRP 64 randomized blinded 64 preclinical efficacy 64 FOLFIRI chemotherapy 64 PRT# 64 Corlux 64 GRAVITAS trial 64 Atrasentan 64 PEG IFN 64 viral kinetic 64 RGB # 64 Pimavanserin 64 ONCONASE R 64 MEND CABG II 64 initiate Phase 1b 64 Pemetrexed 64 Clinicaltrials.gov 64 acyclovir Lauriad ® 64 ocrelizumab 64 Cervista HPV HR 64 ularitide 64 retinal vein occlusion induced 64 olaparib 64 Pharmacodynamic 64 oral rivaroxaban 64 REG1 Anticoagulation System 64 leading oral taxane 64 ZYBRESTAT fosbretabulin 64 pomalidomide 64 subcutaneous PRO 64 EMPOWER ™ 64 Dose Ranging 64 Sibutramine Cardiovascular Outcomes 64 BARACLUDE R 64 Degarelix 64 LymphoStat B 64 oral picoplatin 64 Pazopanib 64 tesmilifene 64 LAF# 64 Acute Ischemic Stroke 64 multicenter randomized Phase III 64 sunitinib Sutent 64 Pivotal Phase II 64 CRMD# 64 confirmatory Phase IIIb 64 IND submission 64 dosing cohorts 64 By JENNIFER LEARN 64 EOquin TM phase 64 PDE4 inhibitor 64 Phase 2b randomized 64 Dapagliflozin 64 novel histone deacetylase 64 Aryplase 64 OLYMPIA registry 64 DXL# 64 MKC# MKC# PP 64 Prednisone Against Refractory 64 Phase 2b monotherapy 64 gefitinib Iressa 64 cancer mCRC 64 farletuzumab 64 VELCADE melphalan 64 identifier NCT# 64 CUSTOM II 64 Xanafide 64 PEG SN# 63 GRN# 63 aclidinium bromide 63 ADMIRE HF 63 developed preclinically 63 MDV# 63 blinded randomized 63 HCV NS5B polymerase 63 genotypic resistance 63 Trandolapril 63 recurrent metastatic 63 fostamatinib 63 clinical pharmacology studies 63 PI3K/Akt pathway inhibitor 63 Prostate Lung Colorectal 63 RANK Ligand inhibitor 63 Seliciclib 63 Estybon ™ 63 Allovectin 7 63 p# biomarker 63 prospective multicenter randomized 63 Allovectin 7 ® 63 RG# [001] 63 alpha 2A adrenoceptor 63 recurrent metastatic ovarian cancer 63 VESTASYNC 63 VEGFR2 inhibitor 63 nonrandomized 63 VICTOR E3 63 photoprotective drug 63 bevirimat Study 63 ACCORD Lipid 63 Intervention Effectiveness CATIE 63 Raptiva R 63 multicenter randomized clinical 63 EndoTAG TM -1 63 Pivotal Clinical Trial 63 OncoVex 63 Solazed 63 Initiates Enrollment 63 tanespimycin 63 cediranib 63 SPIRIT IV 63 Trial Evaluating 63 RhuDex 63 HDAC Inhibitor 63 Aggressive Reduction 63 Advaxis Phase 63 Tocosol Paclitaxel 63 Phase 1b dose escalation 63 vascular disrupting agent 63 Oncotype DX colon cancer 63 Xeloda ® 63 docetaxel Taxotere ® 63 Deforolimus 63 Carfilzomib 63 pharmacokinetics PK 63 #nd EORTC NCI 63 adecatumumab 63 Neuvenge 63 metastatic CRC 63 RSD# oral 63 CCX# B 63 VIRAMUNE XR 63 Daclizumab 63 metastatic renal cell carcinoma 63 CRLX# 63 Pralatrexate 63 relapsed refractory multiple myeloma 63 Dalbavancin 63 RESTORE CLI trial 63 refractory CLL 63 ROCKET AF 63 prospective randomized multicenter 63 Targretin capsules 63 Pivotal Study 63 ATL# [001] 63 HORIZONS AMI 63 Fx #A 63 thorough QT 63 vandetanib 63 RoACTEMRA 63 stage IIIb IV 63 Tarvacin Anti Cancer 63 Advanced Melanoma 63 ENDEAVOR IV clinical 63 Phase 2b clinical trials 63 BLP# Liposome Vaccine 63 Platelet Inhibition 63 Truvada tablets 63 placebo controlled multicenter 63 IMC A# 63 Catena ® 63 multicenter randomized double 63 BENICAR HCT 63 IIb clinical trial 63 TNFerade TM 63 cetuximab Erbitux R 63 randomized controlled clinical 63 KRN# 63 label multicenter Phase 63 reslizumab 63 RELOVAIR ™ 63 Phase III multicenter 63 R sorafenib tablets 63 ritonavir boosted 63 pain palliation 63 TORISEL 63 masked placebo controlled 63 recurrent NSCLC 63 Zolinza 63 Dose escalation 63 ONGLYZA ™ 63 Tipranavir 63 phase III ACCLAIM 63 Romidepsin 63 IIa clinical 63 CCR5 antagonist 63 Reverset 63 lorcaserin Phase 63 Phase #b/#a trial 63 PARTNER Trial 63 glufosfamide 63 varespladib 63 thalidomide Thalomid 63 CTAP# Capsules 63 LymphoStat B belimumab 63 LidoPAIN SP 63 HCD# [002] 63 Lu AA# 63 Dose Escalation 63 untreated metastatic colorectal 63 PD LID 63 dasatinib Sprycel ® 63 ataluren 63 First Patient Enrolled 63 demonstrated antitumor activity 63 Testosterone MDTS R 63 Cimzia TM 63 iPrEx 63 adjuvant colon cancer 63 OvaRex R 63 Proxinium TM 63 Denufosol 63 Kahalalide F 63 Omnitarg 63 active comparator 63 R#/MEM 63 GATTEX ® 63 Contrave# 63 selective androgen receptor modulator 63 Multicenter Randomized 63 Relapsed Multiple Myeloma 63 Certican 63 Virulizin ® 63 morphometric vertebral fractures 63 budesonide MMX Phase III 63 Saxagliptin 63 plasma kallikrein inhibitor 63 Virologic 63 tocilizumab 63 HuMax CD4 63 Panzem R NCD 63 SPIRIT III 63 ZD# [001] 63 SNT-MC#/idebenone 63 PROactive study 63 Canvaxin 63 Dupuytren Contracture 63 Mipomersen 63 regorafenib 63 RRMS patients 63 Phase IIa trials 63 Patient Enrollment 63 Phase IIb Clinical Trial 63 Commence Phase 63 PRECISE trial 63 INCB# [003] 63 XIENCE V PROMUS Stent 63 naïve HCV 63 ARCOXIA 63 terlipressin 63 intravenous methylnaltrexone 63 tenofovir emtricitabine 63 Teriflunomide 63 Panitumumab 63 Ranolazine 63 multiple myeloma MM 63 TRACON Pharmaceuticals 63 Adjuvant Treatment 63 trial evaluating PRX# 63 Folfox 63 BiTE R 63 plus Copegus R 63 memantine HCl 63 AZILECT R 63 ENDEAVOR II 63 ancrod 63 papillary renal cell carcinoma 63 ENMD # 63 Cloretazine R VNP#M 63 Randomized Controlled 63 Cinquil 63 FOLFOX6 chemotherapy regimen 63 lorvotuzumab mertansine 63 Trofex 63 GVAX 63 systemic ALCL 63 HGS ETR1 mapatumumab 63 Successfully Completes Phase 63 BARI 2D 63 ixabepilone 63 budesonide MMX 63 novel oral anticoagulant 63 ritonavir boosted atazanavir 63 mapatumumab 63 TTF Therapy 63 Certolizumab pegol 63 NCT# ClinicalTrials.gov 63 ATAC Arimidex Tamoxifen Alone 63 PTK ZK 63 CIMZIA TM 63 Desmoteplase 63 BAY #-# 63 Acute Decompensated Heart Failure 63 placebo controlled clinical trials 63 AIR CF1 63 R lenalidomide 63 VFEND 63 Confirmatory Phase 63 CB2 selective receptor agonist 63 Telik logo TELINTRA 63 Urocidin 63 Microplasmin 63 elagolix 63 sitaxsentan 63 torezolid phosphate 63 davunetide intranasal AL 63 Preclinical Study 63 AeroLEF TM 63 hoFH 63 Panzem NCD 63 investigational pan BCR 63 Maximum Tolerated Dose 63 Fibrin Pad 63 Demonstrates Positive 62 multicentre 62 LHRH receptor positive 62 baminercept 62 inhaled AAT 62 refractory gout 62 Follicular Lymphoma 62 Phase III Psoriasis 62 Multicenter Automatic Defibrillator Implantation 62 sipuleucel T 62 AEGR 62 bardoxolone 62 NEUVENGE 62 worsening thrombocytopenia 62 Mg Usa 62 #rd Annual CTRC 62 Diabetic Macular Edema 62 NDA Submission 62 STEALTH C 62 nonsmall cell lung cancer 62 Phase III TRIST 62 afatinib 62 CCX# 62 L BLP# 62 Ceflatonin R 62 Cholesterol Levels SPARCL 62 Phase #/#a clinical 62 Prostate Cancer Prevention 62 Arranon 62 refractory acute myeloid 62 Phase III ALLEGRO 62 iniparib 62 ACCORD COPD 62 rilonacept 62 #D#C# 62 Oral Insulin Capsule 62 Jevtana 62 dyskinesia PD LID 62 ENRICH trial 62 multicentre randomized double 62 Sym# 62 RE SURGE 62 HCV Protease Inhibitor 62 Refractory Hodgkin Lymphoma 62 PNP inhibitor 62 Clinical Outcomes Utilizing Revascularization 62 Augment Injectable 62 NCCTG N# 62 GLYX 62 reduce serum phosphate 62 trials RCTs 62 XOMA 3AB 62 Initiates Phase 2b 62 TRITON TIMI 62 Asentar 62 refractory multiple myeloma 62 prospective randomized controlled 62 Phase IIb clinical trials 62 volociximab 62 AZX# 62 VNP#M 62 mg administered orally 62 bicifadine 62 prodrug stimulant 62 NP2 Enkephalin 62 Bosutinib 62 Cell Lymphoma 62 fallopian tube cancers 62 Ganite ® 62 castration resistant prostate cancer 62 Civacir 62 ruboxistaurin 62 OVATURE 62 Phase 2b Trial 62 mg q#h 62 Phase III pivotal 62 Archexin 62 Personalized Immunotherapy 62 alfa 2a 62 Cimzia ® certolizumab pegol